EP0857061A1 - Solubilisation methods - Google Patents
Solubilisation methodsInfo
- Publication number
- EP0857061A1 EP0857061A1 EP96935083A EP96935083A EP0857061A1 EP 0857061 A1 EP0857061 A1 EP 0857061A1 EP 96935083 A EP96935083 A EP 96935083A EP 96935083 A EP96935083 A EP 96935083A EP 0857061 A1 EP0857061 A1 EP 0857061A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- agent
- amphiphile
- solulan
- medicament
- common solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Definitions
- an inorganic material such as a small inorganic molecule or a colloidal substance, for example a colloidal metal.
- a colloidal metal such as colloidal gold, palladium, platinum or rhodium
- a solution of Solulan 16 at a concentration of lOOmg/ml was prepared by addition of 500mg of Solulan to 4.5ml of distilled water and mixing at 60°C until dissolution was achieved.
- a solution of Solulan C24 at a concentration of lOOmg/ml was prepared by addition of 500mg of Solulan C24 to 4.5ml of distilled water and mixing at 60°C until dissolution was achieved.
- a virus suspension (Sabin strains, Types 1, 2, 3) containing 5xl0 8 particles/ml (spun to remove contaminating protein) was diluted 50-fold by addition of 200 ⁇ l of the suspension to 9.9ml of distilled water, yielding a concentration of 10 7 particles/ml.
- the suspension was divided into four equal aliquots of 2.5ml, and dispensed into 7ml screw-capped glass vials.
- 2.5ml of distilled water was added to one aliquot of virus particles and this group was labelled "W” .
- 2.5ml of Solulan C24 (lOOmg/ml) was added to another aliquot and mixed gently. This group was labelled "S”.
- the suspensions prepared as described herein were used to perform 10-fold dilutions in Vero cell cultures,to measure the viability of the polio virus present. The results were expressed as the highest dilution at which 50% cytopathic effects were observed.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9521805 | 1995-10-25 | ||
GBGB9521805.3A GB9521805D0 (en) | 1995-10-25 | 1995-10-25 | Solubilisation methods |
PCT/GB1996/002609 WO1997015289A1 (en) | 1995-10-25 | 1996-10-25 | Solubilisation methods |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0857061A1 true EP0857061A1 (en) | 1998-08-12 |
Family
ID=10782854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96935083A Withdrawn EP0857061A1 (en) | 1995-10-25 | 1996-10-25 | Solubilisation methods |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0857061A1 (en) |
JP (1) | JP2000502990A (en) |
KR (1) | KR19990067028A (en) |
CN (1) | CN1202818A (en) |
AU (1) | AU704292B2 (en) |
BR (1) | BR9611343A (en) |
CA (1) | CA2235487A1 (en) |
GB (1) | GB9521805D0 (en) |
NO (1) | NO981864L (en) |
NZ (1) | NZ320442A (en) |
WO (1) | WO1997015289A1 (en) |
ZA (1) | ZA969016B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9605709D0 (en) * | 1996-03-19 | 1996-05-22 | Cortecs Ltd | Method |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
AU2007266475B2 (en) | 2006-05-30 | 2009-12-03 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
NZ574524A (en) | 2006-08-09 | 2011-07-29 | Intarcia Therapeutics Inc | Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring |
AU2008244523B2 (en) | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
WO2011037623A1 (en) | 2009-09-28 | 2011-03-31 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
EP3302354B1 (en) | 2015-06-03 | 2023-10-04 | i2o Therapeutics, Inc. | Implant placement systems |
AU2017268161B2 (en) | 2016-05-16 | 2020-03-12 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
CA3049034A1 (en) | 2017-01-03 | 2018-07-12 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0012115A1 (en) * | 1978-12-04 | 1980-06-11 | Ciba-Geigy Ag | Pharmaceutical compositions for topical treatment of virus infections |
US4411882A (en) * | 1978-12-21 | 1983-10-25 | Sandoz Ltd. | Galenical compositions |
-
1995
- 1995-10-25 GB GBGB9521805.3A patent/GB9521805D0/en active Pending
-
1996
- 1996-10-25 BR BR9611343-0A patent/BR9611343A/en not_active Application Discontinuation
- 1996-10-25 KR KR1019980702965A patent/KR19990067028A/en not_active Application Discontinuation
- 1996-10-25 JP JP9516406A patent/JP2000502990A/en active Pending
- 1996-10-25 AU AU73178/96A patent/AU704292B2/en not_active Ceased
- 1996-10-25 CN CN96198527A patent/CN1202818A/en active Pending
- 1996-10-25 NZ NZ320442A patent/NZ320442A/en unknown
- 1996-10-25 EP EP96935083A patent/EP0857061A1/en not_active Withdrawn
- 1996-10-25 ZA ZA9609016A patent/ZA969016B/en unknown
- 1996-10-25 WO PCT/GB1996/002609 patent/WO1997015289A1/en not_active Application Discontinuation
- 1996-10-25 CA CA002235487A patent/CA2235487A1/en not_active Abandoned
-
1998
- 1998-04-24 NO NO981864A patent/NO981864L/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9715289A1 * |
Also Published As
Publication number | Publication date |
---|---|
NO981864D0 (en) | 1998-04-24 |
ZA969016B (en) | 1998-04-28 |
BR9611343A (en) | 1999-12-28 |
CA2235487A1 (en) | 1997-05-01 |
KR19990067028A (en) | 1999-08-16 |
AU7317896A (en) | 1997-05-15 |
AU704292B2 (en) | 1999-04-15 |
NO981864L (en) | 1998-06-24 |
WO1997015289A1 (en) | 1997-05-01 |
JP2000502990A (en) | 2000-03-14 |
GB9521805D0 (en) | 1996-01-03 |
CN1202818A (en) | 1998-12-23 |
NZ320442A (en) | 1999-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU704292B2 (en) | Solubilisation methods | |
Wagner et al. | Liposomes produced in a pilot scale: production, purification and efficiency aspects | |
US6258377B1 (en) | Hydrophobic preparations containing medium chain monoglycerides | |
US6368619B1 (en) | Hydrophobic preparations of hydrophilic species and process for their preparation | |
JP2001510810A (en) | Method for solubilizing pharmaceutical active ingredients in water or aqueous vehicle | |
Chaudhari et al. | Nanostructured lipid carriers as a strategy for encapsulation of active plant constituents: Formulation and in vitro physicochemical characterizations | |
CA2460649C (en) | Novel calixarene based dispersible colloidal systems in the form of nanoparticles | |
RU2304430C2 (en) | Method for preparing injection medicinal formulation of phospholipid preparation "fosfogliv" for treatment and prophylaxis of acute and chronic hepatic diseases | |
JP2007525474A (en) | Nanoparticles of polyoxyethylene derivatives | |
CA2048471C (en) | Water-containing liposome system | |
US6165773A (en) | Methods of preserving viruses | |
EP1448167A1 (en) | New use of ethoxylated phytosterols and phytostanols | |
JP6489556B2 (en) | Multi-compartment lipid nanoparticles | |
JPH10510207A (en) | Isolating agent | |
CA2248351A1 (en) | Method for solubilising hydrophylic materials (e.g. proteins) in a hydrophobic solvent | |
CN102125565B (en) | Medicinal composition of 24-methylene cycloartenyl ferulate | |
KR100433363B1 (en) | Epidermal hydrogel formulation containing acyclovir | |
Gregory | Preparation of Liposomes and Oily Formulations by Freeze-Drying of Monophase Solutions | |
CN117224481A (en) | Food-grade O/W quercetin microemulsion, and preparation method and application thereof | |
Elhassan et al. | Preparation and Evaluation of Artemisinin-Freeze Dried Powders with Enhanced Bioavailability | |
JPH013115A (en) | liposome formulation | |
MXPA97004272A (en) | Seized agents | |
MXPA99000275A (en) | Hydrophobic preparations containing monoglycerides of average chain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980518 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: SI PAYMENT 980513 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CORTECS (UK) LIMITED |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 19990901 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1015676 Country of ref document: HK |